Prof. Hans-Joachim Schmoll receives the ESMO Award 2020 for his pioneering work in developing medical oncology as a specialty, while Prof. Nadia Harbeck wins the Lifetime Achievement Award for her global cancer research and education contributions.
The European Society for Medical Oncology has issued its first recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers. The guidelines recommend routine NGS use for four specific cancer types, while also allowing patients to order larger gene panels if feasible and cost-effective. The recomme...
A recent survey of UK professionals found that COVID-19 has caused significant disruptions to psycho-social care for cancer patients, leading to delays in accessing support. The study highlights the need for innovative solutions to address the growing demand for psychological support during the pandemic.
The COVID-19 pandemic has prompted oncology clinicians to prioritize cancer care, leveraging expertise from low-resource settings for guidance. Prioritization involves weighing the benefits and harms of different treatments, considering factors such as patient outcomes and healthcare resource availability.
A new AI-driven system called ModGraProDep has been developed to predict cancer survival and risk. This innovative tool uses probabilistic modeling and machine learning to provide personalized predictions for patients, enabling more effective treatment planning and improved patient outcomes.
The American Society for Radiation Oncology (ASTRO) has released its first clinical guideline on radiation therapy for cervical cancer. The guidelines address indications and best practices for external beam radiation therapy and brachytherapy in postoperative and definitive settings, including the use of chemotherapy and IMRT.
Oncology pharmacy practitioners worldwide are struggling with limited and restricted PPE supply, making it difficult for them to provide high-quality cancer care. In a study, half of the surveyed countries reported impaired access to essential medications, including anti-infective agents and anticancer medications.
The NRG Oncology trial NSABP B-43 found a statistically non-significant, modest reduction in the rate of recurrence among women that received trastuzumab. The study showed an annual IBTR event rate of 0.80% per year in the RT+T group compared to 0.99% per year in the RT group.
Researchers found that patients in Huntsman at Home had reduced hospitalizations, emergency department visits, and cumulative charges compared to controls. The study demonstrated strong evidence for the care model, showing improved patient outcomes while improving value.
The NRG Oncology trial RTOG 1010 found that adding trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival for patients with HER2-positive local and locally advanced esophageal adenocarcinoma. The study also showed no significant differences in treatment-related toxicity between the two arms.
Oncologists are calling for more time spent on education about palliative care and discussing 'bad news' with patients. Research shows cancer doctors have limited coaching in this area, which can impact patient preferences for treatment or palliative care.
The National Comprehensive Cancer Network (NCCN) has published a list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts and include endorsement of 15 existing measures and seven new concepts proposed for development.
A recent study published in Annals of Oncology found that excess body fat in middle to late adulthood increases the risk of developing advanced prostate cancer. Maintaining a healthy weight through healthy eating and exercise can help reduce this risk.
The NRG-CC001 trial found that lowering radiotherapy dose to hippocampal stem cells reduces cognitive toxicity and neurologic symptoms in patients with brain metastases. Patients who received whole-brain radiotherapy with hippocampal avoidance reported improved cognitive function, reduced fatigue, and fewer cognitive symptoms.
A new study found that US patients are less likely to undergo breast conserving therapy compared to European and Asian patients, with a higher rate of mastectomy. The study suggests that insurance coverage and costs may be factors influencing this difference.
A study published in JAMA Oncology found that proton therapy is just as effective as X-ray radiation therapy in treating cancer, but causes fewer side effects and lower hospitalization rates. This could lead to improved quality of life for patients and reduced healthcare costs.
The study found that higher doses of radiation and adding the drug cetuximab did not improve patient survival compared to standard of care chemoradiation. The 5-year overall survival estimate for the standard radiation dose arm was 32.1%, amongst the highest for Stage III NSCLC.
A recent NRG Oncology study found that breast-conserving treatment without surgery is not feasible based on the study's criteria. The study showed a negative predictive value of 77.5% for tumor bed biopsies, which falls short of the required threshold to support omitting surgery.
The NRG Oncology/NSABP B-42 trial found that extending letrozole therapy for five additional years improved disease-free survival in postmenopausal women with HR+ breast cancer. The study showed a 26% decrease in the risk of breast-cancer-free interval events and a 29% reduction in distant recurrence rates.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline for the use of radiation therapy in treating basal and cutaneous squamous cell carcinomas. The guideline provides recommendations on when to use radiation as stand-alone therapy or following surgery, as well as dosing and fractionation schedules.
The NRG Oncology clinical trial found that accelerated partial-breast irradiation (APBI) did not meet the criteria for equivalence to whole-breast irradiation (WBI) in controlling ipsilateral breast tumor recurrence. APBI did show a 1% difference in 10-year cumulative incidence of IBTR compared to WBI.
Results from NRG-GOG 9929 show that ipilimumab is tolerated in the curative treatment of women with lymph node-positive cervical cancer. The trial found a 12-month progression-free survival rate of 81% and overall survival rate of 90%. Future studies are needed to identify therapeutic targets for improved outcomes.
A secondary analysis of the NRG Oncology clinical trial shows that neurocognitive function (NCF) declines in half of patients with high-risk, low-grade gliomas up to a year after receiving temozolomide-based chemoradiotherapy. However, quality of life (QOL) remains stable or improves in these patients, according to the study.
A nationwide survey of over 400 US adults with cancer found that nearly all patients felt confident in their treatment decisions but had gaps in knowledge about potential side effects. The study highlights the need for more informed patient counseling and coordination between oncology disciplines to manage treatment-related side effects.
Gajewski's research found that a 'hot' or T cell inflamed tumour microenvironment is key to unlocking immunotherapy efficacy. STING agonists and targeted therapies are being developed to combat 'cold' tumours with limited immune response.
A new algorithm developed by a Penn Medicine-led team flags patients who would benefit most from advance care planning conversations, leading to improved timely discussions. The study found that 51% of high-priority flagged patients died within six months compared to less than four percent in lower priority group.
A machine-learning model has been developed to predict significant weight loss and need for feeding tube placement in head and neck cancer patients undergoing radiation therapy. The model showed high accuracy in predicting these two endpoints, allowing clinicians to take preventive measures.
A new trial analysis found that women diagnosed with early stages of cancer who undergo lumpectomies and receive either partial or whole breast radiation have equivalent cosmetic outcomes, according to patient and physician ratings. The study's findings aim to guide women seeking breast-conserving therapy for early-stage disease.
A new analysis finds that long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery. The study suggests that patients with high PSAs should continue to receive hormone therapy in addition to radiation, but those with low PSAs may be better off without it.
ECOG-ACRIN announces late-breaking TAILORx data on chemotherapy regimens for early-stage breast cancer. The data, published concurrently in JAMA Oncology, focuses on patients with a score of 26-100 on the 21-tumor gene recurrence score assay.
A substudy of the NRG Oncology clinical trial found that women rated post-lumpectomy partial breast irradiation as equivalent to whole breast irradiation in terms of cosmetic outcomes and satisfaction. The results suggest that PBI may be a viable option for patients seeking to minimize radiation time commitment and healthcare costs.
A phase 2 clinical trial found that combining temsirolimus with chemotherapy improved patient outcomes for patients with relapsed rhabdomyosarcoma. The treatment resulted in a 54.6% event-free survival rate, compared to 69.1% for those receiving temsirolimus.
A recent study found that a standardized medical school exam can bias the entry of diverse and qualified candidates into radiation oncology residency programs. The researchers suggest that using a holistic approach to evaluate applicants could help address these biases, incorporating emotional intelligence and other core competencies.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline recommending the use of radiation therapy in pre-surgical, post-surgical, definitive and palliative settings. The guideline emphasizes a patient-centered approach integrating patients' values and preferences into treatment decisions.
The European Society for Medical Oncology (ESMO) has announced the winners of its annual awards, recognizing Prof. Eric Van Cutsem's pioneering work in gastrointestinal oncology and Dr. Angelo Di Leo's lifetime achievements in cancer research and education. The ESMO Women for Oncology Award was also presented to Prof. Cristiana Sessa, ...
A study published in JAMA Oncology found that introducing a default physician order into electronic health records reduced daily imaging for cancer patients with advanced cancer by half. This change also saved an average of two minutes per session, resulting in faster treatment courses.
Dr. Jerry A. Shields, MD is honored with the 2019 Lucien Howe Medal for his distinguished service to the fields of ocular oncology and ophthalmology. He has made significant contributions to life-saving treatments and cures in eye cancer.
A Penn study shows a Moonshot-funded program can increase cancer patients' engagement in tobacco cessation treatments from 0% to 36%. The program's success is attributed to institutional buy-in and continuous dialogue with clinicians, which informed the development of additional support services.
The NRG-GOG 0258 trial showed that carboplatin and paclitaxel chemotherapy alone resulted in comparable recurrence-free survival rates compared to combined modality treatment. The study found a reduced incidence of vaginal, pelvic, and para-aortic lymph node recurrences but increased distant recurrences with combined modality treatment.
The NRG GOG 0261 clinical trial shows that paclitaxel plus carboplatin is not inferior to paclitaxel plus ifosfamide in treating women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary. The treatment improved overall survival and progression-free survival outcomes.
The study found that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. PBI participants reported less fatigue and were rated more convenient, but experienced slightly poorer cosmesis compared to WBI.
A recent analysis of NRG Oncology/RTOG 9802 data suggests that both IDH-mutant subgroups of high-risk low-grade gliomas may benefit from the addition of PCV chemotherapy to radiotherapy. This finding is significant, as it enhances prognostic and predictive clarification of patients with low-grade glioma.
Researchers found that proton therapy significantly lowers the risk of severe side effects in cancer patients undergoing radiation and chemotherapy, with a relative risk reduction of two-thirds. Cure rates were almost identical between groups.
The number of cardiologists trained in cardio-oncology is not meeting the growing needs of cancer survivors, who are aging and developing co-morbid cardiovascular disease. Limited training programs and resources are emerging to address this need, highlighting the importance of collaboration between cardiologists and oncologists.
The WINTHER trial successfully matched personalized therapy to 35% of patients with advanced cancer, showing improved overall survival for those with a high degree of matching. The trial's strategy employed RNA expression testing to tailor treatment based on gene expression differences between tumors and normal tissues.
Radiation oncologists provide guidance on preparing for and responding to natural disasters, including creating emergency operations plans, providing patients with access to treatment plans via flash drives, and identifying alternative sources of power. The tips aim to minimize treatment delays during a disaster.
NRG Oncology received $95 Million in NCI funding for six years, based on exceptional peer review scores. The organization will focus on increasing accrual, supporting young investigators, and raising awareness of clinical cancer research.
A recent study published in JAMA found that magic mouthwash significantly reduced pain from oral mucositis, a common side effect of radiation therapy for head and neck cancers. The treatment, which contains diphenhydramine, lidocaine, and antacids, was well-tolerated by patients and outperformed placebo.
A USC study found that despite substantial media attention, most cancer drugs in shortage had little to no effect on chemotherapy treatment. Researchers analyzed over 2.4 million claims and found minimal change in treatment for the majority of oncology drugs during shortages.
Professor Jonas Bergh is recognized for his work on breast cancer biology, including tailored treatments and the impact of chemotherapy. He has made significant contributions to primary breast cancer treatment through his involvement in clinical trials and research collaborations.
Francoise Mornex, a renowned French oncologist, has been awarded the prestigious Heine H. Hansen Award for her groundbreaking contributions to the treatment of lung cancer. Her research focuses on combined chemoradiation strategies, multimodality treatment, and innovative radiotherapy techniques.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
A Children's Oncology Group study shows that postoperative radiation improves outcomes for children with ependymoma, achieving seven-year progression-free survival for over 75% of patients and overall survival for 85%. The findings provide evidence that radiation can improve outcomes despite age and tumor subtype.
A recent study published in the Journal of Clinical Oncology found that time to biochemical failure can be used as a surrogate endpoint for locally advanced prostate cancer treatment, reducing overall survival benefit by 6% compared to traditional endpoints. The analysis of NRG-RTOG 9202 clinical trial results showed significant associ...
Researchers have developed techniques to personalize anticancer vaccines based on individual patient genomic information, targeting unique tumor mutations. Early results show promise in inducing potent immune responses.
The ESMO Immuno-Oncology Congress highlighted promising new technologies for cancer treatment, including multiplex immunohistochemistry and bispecific antibodies. Chimeric antigen receptor T-cell therapy and neoantigen therapeutics also showed promise in treating a greater proportion of patients with cancer.
Recent studies at SABCS 2018 highlight radiation therapy's efficacy in treating breast cancer, with trials refining treatments to provide more options for patients. Accelerated partial breast irradiation has been shown to be non-inferior to traditional whole breast irradiation.
Cornelis Melief is recognized for his life's work in studying the interactions of the immune system with cancer, leading to the development of new therapeutic cancer vaccine strategies. His research has shown clinical effectiveness in treating patients with pre-malignant lesions caused by HPV type 16.
Researchers found that targeting tumor sites with radiation or surgery after initial treatment can significantly improve overall survival time for patients. Progression-free survival and toxicity data also showed benefits, with median overall survival times of up to 41.2 months.
Researchers investigated alternative radiation therapy regimens for early-stage breast cancer patients. The trial found that fewer, larger individual doses of radiation led to similar adverse effects as conventional radiation therapy after 10 years.